Amarna Raises Over $5M to Advance Gene Therapy for Hemophilia B

Amarna Raises Over $5M to Advance Gene Therapy for Hemophilia B

313314

Amarna Raises Over $5M to Advance Gene Therapy for Hemophilia B

Amarna Therapeutics has secured €5 million (about $5.6 million) in new funding, which it plans to use for developing its lead product, AMA005, an investigational gene therapy that aims to restore blood clotting in people with hemophilia B. The goal is to advance the company’s hemophilia B program toward a first-in-human clinical study, Amarna said in a press release. The new funds are from existing backers C4 holding BV, Flerie Invest AB, and RVO, the…

You must be logged in to read/download the full post.